

Article/Review

Gipertrofik kardiomiopatiyaning obstruktiv shaklida yurakning remodellashuv xususiyatlari, Morrou bo'yicha mioektomiyaning samaradorligi

N. Rasulova ^{*1} , T.A. Abdullayev ² , A.A. Hakimov ³ 

¹ Qabul bo'limi, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi, Shahar, indeks, Mamlakat

² Yurak yetishmovchiligi va miokardning nokoronorogen kasalliklari bolimi, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi, ³ Minimal invaziv yurak jarrohligi va operatsiyadan keyingi reabilitatsiya bolimi, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi, nargisrasulova2@gmail.com (N.R.), escardio@mail.ru (T.A.), adhamjon.hakimov077@gmail.com (A.H.)

* Correspondence: nargisrasulova2@gmail.com; Tel.: +998 90 0913170 (A.H.)

Annotatsiya:

Obstruktiv gipertrofik kardiomiopatiya (OGKMP)– genetik omillar tufayli yurakning remodellashuvi bilan kechuvchi kasallikdir. OGKMP chap qorinchaning chiqish yolida dinamik obstruksiya, diastolik disfunktsiya, mitral regurgitatsiya, miokard ishemiyasi va yurak ritmi buzilishlari rivojlanishiga sabab bolishi mumkin. Klinik jihatdan bemorlarda yurak yetishmovchiligi belgilari bilan namoyon boladi. OGKMP, ayniqsa, yoshlarda va sportchilar orasida to'satdan yurak o'limining eng keng tarqalgan sababi hisoblanadi. AQSh va Yevropa davlatlarida otkazilgan epidemiologik kuzatuv natijalariga ko'ra, 35 yoshgacha bo'lgan sportchilarda to'satdan yurak o'limi 30–40% holatlarda OGKMP bilan bog'liq. Bugungi kunda, kasallikni davolashning zamonaviy noinvaziv usullari mavjudligiga qaramay, xirurgik usul samaradorligi ustun kelmoqda. Maqolada ushbu kasallikda yurakning remodellashuv xususiyatlari, ushbu yonalishda olib borilgan klinik tadqiqotlar natijalari va davo usullarining samaradorligi haqida adabiyotlarda keltirilgan ma'lumotlar tahlil qilinadi.

Kalit so'zlar: gipertrofik kardiomiopatiya, Morrou mioektomiyasi, diastolik disfunktsiya, yurakning remodellashuvi.

Iqtibos: N. Rasulova, T.A. Abdullayev, A.A. Hakimov. Gipertrofik kardiomiopatiyaning obstruktiv shaklida yurakning remodellashuv xususiyatlari, Morrou bo'yicha mioektomiyaning samaradorligi. 2025, 2,3, 9. <https://doi.org/10.70626/cardiouz-2025-2-00058>

Olingan: 10.07.2025

Tuzatilgan: 18.07.2025

Qabul qilingan: 25.09.2025

Nashr qilingan: 30.09.2025

Copyright: © 2025 by the authors. Submitted to for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Heart remodeling in the obstructive form of hypertrophic cardiomyopathy, efficacy of Morrow septal myectomy

Nargis Rasulova ^{*1} , Timur A.Abdullayev ² , Adhamjon A.Hakimov ³ 

¹ Admission Department, Republican Specialized Scientific and Practical Medical Center of Cardiology, City, Postal Code, Country

² Department of Heart Failure and Non-Coronary Myocardial Diseases, Republican Specialized Scientific and Practical Medical Center of Cardiology

³ Department of Minimally Invasive Cardiac Surgery and Postoperative Rehabilitation, Republican Specialized Scientific and Practical Medical Center of Cardiology

nargisrasulova2@gmail.com (N.R.), escardio@mail.ru (T.A.), adhamjon.hakimov077@gmail.com (A.H.)

Abstract:

Obstructive hypertrophic cardiomyopathy (OHCMP) is a disease characterized by cardiac remodeling due to genetic factors. OHCMP can cause the development of dynamic obstruction in the outflow tract of the left ventricle, diastolic dysfunction, mitral regurgitation, myocardial ischemia, and cardiac arrhythmias. Clinically, patients are manifested by symptoms of heart failure. OHCMP is the most common cause of sudden cardiac death, especially in young people and among athletes. According to the results of epidemiological observations conducted in the USA and European countries, sudden cardiac death in athletes under 35 years of age is associated with OHCMP in 30–40% of cases. Today, despite the availability of modern non-invasive methods of treating the

disease, the effectiveness of the surgical method prevails. The article analyzes the data presented in the literature on the features of cardiac remodeling in this disease, the results of clinical studies conducted in this area, and the effectiveness of treatment methods.

Keywords: hypertrophic cardiomyopathy, Morrow myectomy, diastolic dysfunction, cardiac remodeling.

Kirish

Gipertrofik kardiomiopatiya (GKMP) — bu yurak mushak qavatining, aksariyat holatlarda chap qorincha devorining (kopincha qorinchalararo tosiqning) qalinlashuvi (gipertrofiyasi) bilan tavsiflanadigan genetik kasallikdir [21]. Bu holat yurakning qon bilan tolishi va qon haydashini qiyinlashtiradi, yurakning elektr va mexanik faoliyatini buzilishiga sabab boladi [1].

GKMP autosomal-dominant yol bilan irsiylanuvchi kasallik bolib, uchrash chastotasi 1:500 [13, 21]. Patogen ozgarishlar MYH7 va MYBPC3 kabi genlarda sodir bolib [11,16], sarkomer oqsillarning relaksatsiyasini ozgartiradi, kaltsiy almashinuviga ta'sir etadi va energiya talabini oshiradi [1]. Bemorlarning taxminan 60%da sarkomer ozgarishlar aniqlanmaydi, ba'zi bemorlarda oilaviy anamnez yoki poligen etiologiya mavjud [8]. GKMP erkaklar va ayollar ortasida deyarli teng darajada uchraydi [21]. Kasallik har qanday yoshda, shu jumladan bolalik davrida ham aniqlanishi mumkin. Biroq klinik simptomlar kopincha 15–35 yosh oraliqida namoyon boladi [13]. Aynan shu yoshdagi bemorlarda yurak gipertrofiyasi klinik belgilari namoyon bola boshlaydi. Shuningdek, kasallik osmirlik davrida aniqlanmagan bolsa, yoshi ulgayganda tosatdan yurak olimi korinishida birinchi marta namoyon bolishi mumkin [5]. Bugungi kunda GKMP tashxisi uchun asosiy mezon bu- chap qorincha diastolik disfunktsiya mavjud bolgan holda miokard qalinligi 1,5 sm va undan ortiq bolishidir [21].

Chap qorincha chiqish yolida obstruksiya mavjudligiga kora GKMPning obstruktiv va noobstruktiv shakllari tafovut qilinadi [10]. Obstruktiv gipertrofik kardiomiopatiya (OGKMP)-obstruksiya natijasida chap va/yoki ong qorinchadan aortaga qon haydalishining buzilishi hisobiga intrakardial gemodinamik buzilishlar bilan kechuvchi, chap va/yoki ong qorinchaning chiqish yolida bosim gradientining ortishiga sabab boluvchi GKMP shakli hisoblanadi [11].




Figure 1. Cardiac Remodeling in Hypertrophic Cardiomyopathy
Rasm 1. Gipertrofik kardiomiopatiyada yurakning remodellashuvi

Obstruktiv gipertrofik kardiomiopatiyada yurakning remodellashuv xususiyatlari. OGKMP yurakdagi sezilarli struktur va funksional ozgarishlar bilan tavsiflanib, ayniqsa chap qorinchaning chiqish yolidagi (ChQChY) ozgarishlar bilan kechadi. Aksariyat hollarda asimmetrik gipertrofiya kuzatilib, bazal tosiqning qalinlashuvi natijasida ChQChY torayadi, bu esa sistolik obstruksiyanı yuzaga keltiradi [6]. Bazi bemorlarda esa gipertrofiya konsentrik korinishda bolib,

butun miokard devorining qalinlashishi va chap qorincha boshligining torayishi bilan namoyon boladi [8]. (1-rasm)

OGKMPda yurakning struktur remodelanishi quyidagi o'zgarishlarni o'z ichiga oladi: miokard gipertrofiyasi, kichik tomirlardagi ishemiya, hamda fibroz (to'qima chandiqlanishi) [20]. Bu o'zgarishlar nafaqat sarkomer oqsillarni kodlovchi genlardagi mutatsiyalar, balki ChQChYda yuzaga keladigan gemodinamik yuklama kabi ikkilamchi omillar bilan ham bog'liq [1].

OGKMP mavjud bemorlarda miokard toqimasini mikroskopik organilganda, kardiomiotsitlarning tartibsiz joylashuvi (disarray syndrome) [6] va interstitsial fibroz aniqlandi. Ushbu ozgarishlar miokardning elastikligini kamaytirib, mushak toqimasining qattiqqligini oshiradi, bu esa diastolik disfunktsiya, aritmogen holatlar va boshqa funksional buzilishlar rivojlanishiga sabab boladi [10]. Shuningdek, miokard gipertrofiyasi darajasi ko'pincha miokard devori zo'riqlanishini va kasallik og'irligini aks ettiruvchi biologik ko'rsatkichlar — ya'ni miya natriyuretik peptidi (BNP) va N-terminalli pro-BNP (NT-proBNP) darajalarining oshishi bilan bog'liqligi aniqlangan [7].

Miokardning gipertrofiyasi va fibrozlanishi yurakning diastolik disfunktsiyasiga sabab boladi— qorincha diastola paytida tola kengaya olmaydi. Natijada chap qorinchaning qon bilan tolishi qiyinlashib, intraventrikulyar diastolik bosim oshadi [19]. Bu holat yurakning “gemodinamik siqilishiga” olib kelib, vaqt o'tishi bilan chap bolmacha kengayadi [6]. OGKMP mavjud bemorlarida otkazilgan septal mioektomiya jarohatidan keyin ham chap bolmacha hajmi normal korsatkichlarga qaytmasligi kuzatilgan [21]— bu diastolik disfunktsiya natijasida bolmacha turgun kengayganini anglatadi. Deyarli barcha OGKMP mavjud bemorlarida malum darajada diastolik disfunktsiya mavjud bolib, bu ularda yurak yetishmovchiligi (YY) alomatlarini keltirib chiqaradi [6].

OGKMPda yurakning anatomik tuzilishi ham ozgaradi. Gipertrofiyalashgan qorinchalararo tosiq va kichik hajmli chap qorincha boshligi “banansimon” geometrik shaklni egallaydi [18]. Shu bilan birga, mitral klapan apparatining anomaliyalari (qopqoqchalar elongatsiyasi yoki ortiqcha toqimalar, papillyar mushaklarning gipertrifikatsiyasi va notogri joylashishi) rivojlanadi [19]. Natijada sistola paytida mitral klapan oldingi varagingning patologik oldinga siljishi — “sistolik oldingi harakat” (SAM fenomeni) yuzaga keladi [1]. SAM fenomeni [19] mitral qopqoq tabaqasi va qalinlashgan tosiqning kontaktiga sabab bolib, chiqish yo'lini yanada toraytiradi va ikkilamchi mitral yetishmovchilikni keltirib chiqaradi. Shunday qilib, OGKMPda anatomik (tosiq va qopqoqchalar tuzilishi) va funksional (dinamik SAM) ozgarishlar kombinatsiyasi yurakning patologik remodelashuvini belgilaydi [3].

Morrou boyicha mioektomiya samaradorligi. Morrou boyicha transaortal septal mioektomiya — OGKMPda chap qorinchaning chiqish yo'lida yuzaga kelgan obstruksiyanı bartaraf etishda oltin standart hisoblanadi [21]. Ushbu operatsiya davomida qalinlashgan qorinchalararo tosiqning ma'lum bir qismi (odatda 5–10 gramm to'qima) [10] rezeksiya qilinadi va natijada chiqish traktining fiziologik kengligi tiklanadi. Amaliy natijada ChQChY obstruksiyasi sezilarli darajada kamayadi, SAM-fenomen (mitral klapaning tosiqqa tortilishi) sabab yuzaga kelgan mitral regurgitatsiya darhol kamayadi [9,10]. Bu o'zgarishlar yurak ichki bosimini me'yorlashuvi va bemorning gemodinamik holati yaxshilanishi, klinik simptomlarning kamayishi bilan namoyon boladi [2].

Morrou boyicha mioektomiya chiqish yo'lidagi obstruksiyanı bartaraf etib, subaortal gradientni deyarli nol darajasiga tushiradi [10]. Keng ko'lamli tadqiqotlarda operatsiyadan so'ng ChQChY gradienti o'rtacha 50–90 mm.sim.ust. dan 5–10 mm.sim.ust. gacha kamaygani aniqlangan [12,14]. Masalan, otkazilgan markaziy tadqiqotda mioektomiya natijasida ChQChY bosim gradienti 89 mm mm.sim.ust.dan 16 mm.sim.ust. pasaygan; mitral regurgitatsiya og'irligi esa bemorlarning 78%ida mo'tadil- og'ir darajadan atigi 7%gacha tushgan [12].

Morrou boyicha septal mioektomiya ochiq yurak operatsiyasi bo'lib, uning oziga xos ayrim asoratlar mavjud. Biroq tajribali markazlarda 30 kunlik o'lim darajasi atigi 0,5–1% ni tashkil etadi [5]. Eng keng tarqalgan asorat - atrioventrikulyar blokada bo'lib [8] bu holat Giss tutami zararlanishi bilan bog'liq va bemorlarning 2–5%ida doimiy elektrokardiostimulyator o'rnatishni talab qiladi [22]. Qorinchalararo to'siqning chuqur rezeksiyasi natijasida tosiq defekti rivojlanishi (1%) mumkin [15]. Operatsiyadan keyin yurak ritm buzilishlari, xususan bolmachalar fibrillyatsiyasi 20% gacha bemorlarda kuzatilgan [17,22]. Kam hollarda esa insult (<1%) yoki boshqa tromboembolik asoratlar qayd etiladi [15]. Reabilitatsiya davri o'rtacha 6–9 kun davom etadi [10]. Shunga qaramay, tajribali jamoalar ishtirokida bu asoratlarning chastotasi minimal darajada bo'ladi.

2014 yilda bir guruh amerikalik mualliflar 1998-2010 yillar oraligida 665 bemorda ChQChY obstruksiyasini jarrohlik yoli bilan davolashning uzoq muddatli natijalarini tavsiflovchi kop markazli tadqiqot natijalarini nashr etdilar. Umumiy shifoxona olimi 5,9% ni tashkil etdi. 8,7% hollarda toliq AV blokadası tufayli doimiy yurak stimulyatori implantatsiyasi talab qilingan [15].

Klinik jihatdan, 94% ga yaqin bemorlarda YY simptomlari NYHA bo'yicha I-II funksional sinfgacha yaxshilanishga erishilishi kuzatilgan [2]. Ya'ni hansirash, ko'krak sohasida og'riq, sinkope kabi simptomlar sezilarli darajada kamaygan. Septal mioektomiya nafaqat simptomlarni bartaraf etadi, balki bemorlarning uzoq muddatli hayot davomiyligini oshiradi [2]. Tadqiqotlarga ko'ra [9]: 5 yillik tirik qolish – 94%; 10 yillik tirik qolish – 90%ni tashkil etadi. Bu ko'rsatkichlar sog'lom populyatsiya bilan taqqoslaganda ahamiyatli farq qilmaydi. Bemorlarning 90% dan ortig'i yillar davomida simptomsiz hayot kechirishga muvaffaq bo'lgan [2].

To'satdan yurak o'limi va og'ir aritmiyalar chastotasi mioektomiya o'tkazilgan bemorlarda pasayadi yoki o'zgarishsiz qoladi [3]. Shu bilan birga, genetik va miokardial substrat saqlanib qolishi mumkinligi sababli, ayrim holatlarda implantatsiyalanuvchi defibrilliyator (IDF) tavsiya qilinadi [22]. Mioektomiya aritmogenezni to'liq bartaraf qilmasada, yurakning nasos funksiyasini yaxshilaydi va yurak yetishmovchiligi xavfini kamaytiradi [2].

Toronto klinikasida 649 nafar OGKMP bemorlari ustida olib borilgan tadqiqotda invaziv muolaja olgan bemorlarning 10 yillik tirik qolish ko'rsatkichi – 87,8%, faqat dori bilan davolanganlarda esa 75,8% ($p=0.008$) bo'lgan [9]. Shu bois, simptomatik OGKMPda medikamentoz terapiya yetarli bo'lmasa, invaziv muolajalar — mioektomiya yoki alkogol ablatsiyasi tavsiya etiladi [23]. Invaziv usullar simptomlarni kamaytiradi va hayot davomiyligini uzaytiradi, biroq OGKMPning genetik-asosiy xavflarini- masalan, aritmiyalarni- to'liq yo'q qila olmaydi.

Mioektomiya va alkogol septal ablatsiyasi (ASA) [4]- chap qorincha chiqish yoli obstruksiyasini bartaraf etishga qaratilgan ikki asosiy invaziv muolajadir.

ASA [17]: kam invaziv, ammo ablatsiya orqali sun'iy chuqurcha hosil qilinadi. Davolash samarasi uchun 3–6 oy vaqt talab qilinadi [4]. Klinik samaradorlik jihatidan ikkala usul ham NYHA bo'yicha simptomlarni yaxshilaydi [2]. 10 yillik tirik qolish: mioektomiya – 85%, ASA – 82% (farq ahamiyatsiz) [2,17].

Asoratlar farqi:

- ASA: AV-qamal xavfi yuqoriroq- 10–20% bemorlarga implantatsiyalanuvchi defibrilliyator (IDF) kerak bo'ladi [17].
- Mioektomiya: doimiy implantatsiyalanuvchi defibrilliyator (IDF) zarurati 2–4% atrofida [22].
- Takroriy aralashuv ehtiyoji: ASA – 10–15%, mioektomiyada- kam (<5%) [2,17].

Umuman olganda, mioektomiya ko'pincha bir martalik samarali yechim hisoblanadi, ASA esa muayyan guruh bemorlar (yoshi katta, operatsion xavfi yuqori) uchun tavsiya etiladi.

Xulosa

Yuqoridagi malumotlar OGKMP holatlarida septal mioektomiya hozircha eng yuqori klinik samaradorlikka ega usul bo'lib qolayotganini ko'rsatadi: u ChQChY obstruksiyasini deyarli to'liq bartaraf etadi, transaortal bosim gradientini keskin pasaytiradi va uzoq muddatli omon qolish hamda hayot sifatini yaxshilaydi. ASA esa kamroq invaziv alternativ sifatida tanlanishi mumkin; u ham simptomlarni yengillashtiradi va ayrim kogort tadqiqotlarda uzoq muddatli natijalari jarrohlik aralashuviga yaqinlashadi. Optimal strategiyani tanlashda markazning tajribasi, bemorning yoshi, yondosh kasalliklar, qorinchalararo tosiqning qalinlashuv darajasi, mitral klapan va papillyar mushaklarning anatomik xususiyatlari, shuningdek koronar qon tomirlarning xususiyatlari hisobga olinadi.

Mualliflarning hissalari

Konseptualizatsiya, T.A.; metodologiya, N.R.; dasturiy ta'minot, N.R.; tasdiqlash, T.A., rasmiy tahlil, T.A.; tadqiqot, N.R.; resurslar, N.R.; ma'lumotlarni kuratorlik qilish, T.A.; original matnni yozish, N.R.; yozish va tahrirlash, N.R., Hakimov A.A.; vizualizatsiya, N.R., Hakimov A.A.; rahbarlik, T.A.; loyiha boshqaruvi, T.A.; moliya jalb qilish, T.A.. Barcha mualliflar nashr qilingan qo'lyozma versiyasi bilan tanish va u bilan rozi.

Authors' contribution.

Conceptualization, T.A.; methodology, N.R.; software, N.R.; validation, T.A.; formal analysis, T.A.; investigation, N.R.; resources, N.R.; data curation, T.A.; writing — original draft preparation, N.R.; writing — review and editing, N.R., Hakimov A.A.; visualization, N.R., Hakimov A.A.; supervision, T.A.; project administration, T.A.; funding acquisition, T.A. All authors have read and agreed to the published version of the manuscript.

Moliyalashtirish

Ishga tashqi moliya ajratilmagan.

Funding source.

This research received no external funding.

Etika tamoyillariga muvofiqlik

Tadqiqot Xelsinki Deklaratsiyasiga muvofiq o'tkazildi va Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi tomonidan tasdiqlangan.

Ethics approval.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Republican Specialized Scientific and Practical Medical Center of Cardiology.

Nashrga xabardor qilingan rozilik.

Barcha tadqiqot ishtirokchilaridan xabardor qilingan rozilik olindi.

Consent for publication.

Informed consent was obtained from all participants involved in the study.

Ma'lumotlar mavjudligi to'g'risidagi bayonot

Tadqiqotda keltirilgan barcha ma'lumotlar adabiyotlar ro'yxatida ko'rsatilgan manbalardan olingan.

Data Availability Statement

All data presented in the study are derived from the sources listed in the reference section.

Rahmatnomalar

Taqdim etilgan barcha ma'lumot manbaalari adabiyotlar royxatida korsi tilgan.

Acknowledgments

Mualliflar o'zlarining manfaatlar to'qnashuvi yo'qligini e'lon qiladilar.

Manfaatlar to'qnashuvi

Mualliflar o'zlarining manfaatlar to'qnashuvi yo'qligini e'lon qiladilar.

Conflict of interest

The authors declare no conflicts of interest.

Qisqartmalar

ASA alkogol	septal ablyatsiya
ChQChY	chap qorincha chiqish yo'li
GKMP	gipertrofik kardiomiopatiya
IKD	implantatsion kardioverter defibrilyator
IVT	interventrikulyar tosiq
MR	mitral regurgitatsiya
NYHA	Nyu York Yurak Assotsiatsiyasi
OGKMP	obstruktiv gipertrofik kardiomiopatiya
TYO	to'satdan yurak o'limi
YY	yurak yetishmovchiligi

Adabiyot

- [1] Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivetto I (2023) Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 44(44):4622–4633.

- [2] Capota R, Militaru S, Ionescu AA, Rosca M, Baicus C, Popescu BA et al (2020) Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. *Health Qual Life Outcomes* 18:1–8.
- [3] Dong T, Alencherry B, Ospina S, Desai MY (2023) Review of mavacamten for obstructive hypertrophic cardiomyopathy and future directions. *Drug Des Devel Ther* 17:1097–1106.
- [4] Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcatheter septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise outcomes. *Eur Heart J* 2002;23:1617–24. <https://doi.org/10.1053/ehj.2002.3285>.
- [5] Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2020;75(21):2649–2660. <https://doi.org/10.1016/j.jacc.2020.03.064>.
- [6] Keen, S., Desai, M. Y. (2025). Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal. *Future Cardiology*, 21(7), 527–537. <https://doi.org/10.1080/14796678.2025.2501466>.
- [7] Kubo T, Ochi Y, Baba Y, Sugiura K, Takahashi A, Hirota T et al (2020) Elevation of high-sensitivity cardiac troponin T and left ventricular remodelling in hypertrophic cardiomyopathy. *ESC Heart Fail* 7(6):3593–3600.
- [8] Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. *N Engl J Med* 390:1849–1861.
- [9] Masri A, Cardoso RN, Abraham TP, et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy. *J Am Coll Cardiol.* 2024;84(19):1806–1817. <https://doi.org/10.1016/j.jacc.2024.08.015>.
- [10] Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. *Ann Surg* 1961;154:181–89. <https://doi.org/10.1097/00000658-196108000-00003>.
- [11] Ntelios D, Georgiou E, Alexouda S, Malousi A, Efthimiadis G, Tzimagiorgis G (2022) A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy. *Heart Fail Rev* 27:281.
- [12] Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2020;396:759–769.
- [13] Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American heart Association/American college of cardiology joint committee on clinical practice guidelines. *Circulation.* 2024;149(23):e1239–e1311. <https://doi.org/10.1161/CIR.0000000000001250>.
- [14] Rader F, Oreziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. *JACC Heart Fail.* 2024;12(1):164–177. <https://doi.org/10.1016/j.jchf.2023.09.028>.
- [15] Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, Wang W, Carpio P, Maron BJ, Maron MS, Chen FY. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. *Ann Car diothorac Surg.* 2017 Jul;6(4):353–363. <https://doi.org/10.21037/acs.2017.07.07>. PMID: 28944176; PMCID: PMC5602194.
- [16] Sarwer, K., Lashari, S., Rafaqat, N. et al. Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond. *Egypt Heart J* 76, 156 (2024). <https://doi.org/10.1186/s43044-024-00587-y>.
- [17] Smedira, N. G., Lytle, B. W., Lever, H. M., Rajeswaran, J., Krishnaswamy, G., Kaple, R. K., Dolney, D. O., Blackstone, E. H. (2008). Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. *The Annals of thoracic surgery*, 85(1), 127–133. <https://doi.org/10.1016/j.athoracsur.2007.07.063>.
- [18] Watkins H (2021) Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. *Circulation* 143(25):2415–2417.
- [19] Yun Zhao, Chenhe Li, Dazhong Tang, Yi Luo, Chunlin Xiang, Lu Huang, Xiaoyue Zhou, Jing Fang, Xiang Wei, Liming Xia, Early reverse remodeling of left heart morphology and function evaluated by cardiac magnetic resonance in hypertrophic obstructive cardiomyopathy after transapical beating-heart septal myectomy, *Journal of Cardiovascular Magnetic Resonance*, Volume 25, Issue 1, 2023, 70, ISSN 1097-6647, <https://doi.org/10.1186/s12968-023-00987-0>.

- [20] Zhu A, Bews H, Cheung D, Nagalingam RS, Mittal I, Goyal V et al (2020) Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study. *Can J Physiol Pharmacol* 98(7):459–465.
- [21] Bockeria L.A., Shlyakhto E.V., Gabrusenko S.A., Gudkova A.Ya., Koziolova N.A., Aleksandrova S.A., Alekhin M.N., Afanasyev A.V., Bogatyreva M.M., Bogachev-Prokofiev A.V., Bogdanov D.V., Berseneva M.I., Gordeev M.L., Dzemeshevich S.L., Evtushenko A.V., Zaklyazminskaya E.V., Zenchenko D.I., Irtyuga O.B., Kaplunova V.Yu., Kashtanov M.G., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Rud S.D., Rybka M.M., Saidova M.A., Streltsova A.A., Stukalova O.V., Chmelevsky M.P., Shaposhnik I.I., Shloydo E.A. Hypertrophic Cardiomyopathy. Clinical Guidelines 2025. *Russian Journal of Cardiology*. 2025;30(5):6387. <https://doi.org/10.15829/1560-4071-2025-6387>. EDN:BUUCJT.
- [22] Raskin V.V., Frolova Yu.V., Malikova M.S., Dzemeshevich A.S., Dombrovskaya A.V., Shapieva Albina Nurullayevna, Fedulova S.V., Dzemeshevich S.L. (2014). Surgical Treatment Strategy for Patients with the Generalized Form of Obstructive Hypertrophic Cardiomyopathy. *Clinical and Experimental Surgery*, 1(3), 100–103.
- [23] Seidalin A.O., Albazarov A.B., Tozhiboev R.E., Nurakaeva S.S., Sygai A.I., Dikolaev V.D. (2015). Surgical Treatment of Obstructive Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine of Kazakhstan*, 1(35), 21–25.

Nashriyot javobgar emas/ eslatmasi:

Barcha nashrlarda keltirilgan bayonotlar, fikrlar va ma'lumotlar faqat mualliflar va ishtirokchilarga tegishlidir, na Jurnal va na muharrirlar. Jurnal va muharrirlar, mazkur kontentda keltirilgan har qanday g'oyalar, usullar, ko'rsatmalar yoki mahsulotlar natijasida insonlar yoki mulkka yetkazilgan har qanday zarar uchun javobgar emas.

Disclaimer of liability/Publisher's Note: The statements, opinions and data contained in all publications belong exclusively to individuals. The authors and participants, and the Journal and the editors. The journal and the editors are not responsible for any damage caused to people or property resulting from any ideas, methods, instructions or products mentioned in the content.